Global NeurologyPub Date : 2019-09-10DOI: 10.36879/gon.20.000101
{"title":"Subclinical atrial fibrillation and risk of stroke: An update","authors":"","doi":"10.36879/gon.20.000101","DOIUrl":"https://doi.org/10.36879/gon.20.000101","url":null,"abstract":"Stroke is one of the major causes of death and disability. Atrial fibrillation causes 15% of strokes, 60% is caused by cerebrovascular disease,\u0000whereas 25% of cases have no known cause. The technological advancement of cardiac implanted electronic devices has enabled the identification\u0000of subclinical atrial fibrillation (SCAF). The literature shows that SCAF is very frequent in the elderly population and that it represents a risk factors\u0000for the onset of stroke or systemic embolic disease, regardless of other cardiovascular risk factors. While for clinical atrial fibrillation (AF) the\u0000advantages of anticoagulant therapy based on the CHA2\u0000DS2\u0000-VASC score have been well established, much has been said about the usefulness of\u0000anticoagulant therapy in the case of SCAF. The role of AF and CHA2\u0000DS2\u0000-VASC score is much debated. A study has recently clearly shown how the\u0000SCAF burden together with CHA2\u0000DS2\u0000-VASC score play an important role in determining the risk of progression to persistent AF. Based on these\u0000data, the ongoing ARTESIA and AFNET-NOAH studies will provide us with data to evaluate the efficacy of anticoagulant therapy in SCAF.","PeriodicalId":230111,"journal":{"name":"Global Neurology","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133809177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}